GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

ClinicalTrials.gov ID: NCT00617279

Public ClinicalTrials.gov record NCT00617279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:13 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Comparison of Primary Patency Between GORE PROPATEN Vascular Graft and Disadvantaged Autologous Vein Graft For Below-Knee Arterial Bypass (PRODIGY Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.

Study identification

NCT ID: NCT00617279
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 4
Lead sponsor: W.L.Gore & Associates; Industry
Enrollment: 31 participants

Conditions and interventions

Conditions

Peripheral Arterial Occlusive Disease

Interventions

GORE PROPATEN Vascular Graft Device
Disadvantaged Autologous Vein Graft Procedure

Device · Procedure

Eligibility (public fields only)

Age range: 21 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2007 (Type not available)
Primary completion: Feb 2010 (Actual)
Completion: Feb 2010 (Actual)
Last update posted: Jan 12, 2012

2007 – 2010

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
University Of Alabama Medical Center	Birmingham	Alabama	35294	—
Georgetown University Hospital	Washington D.C.	District of Columbia	20007	—
Emory University School of Medicine	Atlanta	Georgia	30322	—
Medical Center of Central Georgia	Macon	Georgia	31201	—
University of Chicago	Chicago	Illinois	60637	—
Vascular Specialty Associates	Baton Rouge	Louisiana	70809	—
University of Maryland Medical Center	Baltimore	Maryland	21201	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
Albany Medical Center	Albany	New York	12208	—
Stonybrook University Medical Center	Stony Brook	New York	11794	—
Montifiore Medical Center	The Bronx	New York	10467	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Greenville Hospital System	Greenville	South Carolina	29605	—
University of Tennessee medical Center	Knoxville	Tennessee	37920	—
The Methodist Hospital System	Houston	Texas	77030	—
Peripheral Vascular Associates	San Antonio	Texas	78205	—
Sentara Norfolk Hospital	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00617279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 12, 2012 · Synced Nov 1, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00617279 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →